|Project Title||Principal Investigator||Institution|
|Caspr2 dysfunction in autism spectrum disorders||Robbins, Elissa||Yale University|
|Integrated approach to the neurobiology of autism spectrum disorders||Vaccarino, Flora||Yale University|
|Cellular and genetic correlates of increased head size in autism spectrum disorder||Vaccarino, Flora||Yale University|
|Using zebrafish and chemical screening to define function of autism genes||Sive, Hazel||Whitehead Institute for Biomedical Research|
|Transgenic mouse model to address heterogeneity in autism spectrum disorders||Blakely, Randy||Vanderbilt University|
|Mouse genetic model of a dysregulated serotonin transporter variant associated with autism||Veenstra-Vanderweele, Jeremy||Vanderbilt University|
|Murine genetic models of autism||Veenstra-Vanderweele, Jeremy||Vanderbilt University|
|Evaluation of altered fatty acid metabolism via gas chromatography/mass spectroscopy and time-of-flight secondary ion mass spectroscopy imaging in the propionic acid rat model of autism spectrum disorders||MacFabe, Derrick||University of Western Ontario|
|Deriving neuroprogenitor cells from peripheral blood of individuals with autism||Fujinami, Robert||University of Utah|
|Shank3 mutant characterization in vivo||Kouser, Mehreen||University of Texas Southwestern Medical Center|
|Identifying impairments in synaptic connectivity in mouse models of ASD||Speed, Haley||University of Texas Southwestern Medical Center|
|Animal models of autism: Pathogenesis and treatment||Powell, Craig||University of Texas Southwestern Medical Center|
|Novel genetic animal models of autism||Powell, Craig||University of Texas Southwestern Medical Center|
|Neuroligin function in vivo: Implications for autism and mental retardation||Powell, Craig||University of Texas Southwestern Medical Center|
|Animal model of speech sound processing in autism||Kilgard, Michael||University of Texas at Dallas|
|Behavioral and physiological consequences of disrupted Met signaling||Levitt, Pat||University of Southern California|
|Neurobiology of sociability in a mouse model system relevant to autism||Brodkin, Edward||University of Pennsylvania|
|High-resolution diffusion tensor imaging in mouse models relevant to autism||Poptani, Harish||University of Pennsylvania|
|Functional genomic dissection of language-related disorders||Fisher, Simon||University of Oxford|
|Neuropharmacology of motivation and reinforcement in mouse models of autistic spectrum disorders||Malanga, C.J.||University of North Carolina School of Medicine|
|Preclinical testing of novel oxytocin receptor activators in models of autism phenotypes||Pedersen, Cort||University of North Carolina at Chapel Hill|
|Novel strategies to manipulate Ube3a expression for the treatment of autism and Angelman syndrome||Roth, Bryan||University of North Carolina at Chapel Hill|
|Preclinical testing of novel oxytocin receptor activators in models of autism phenotypes||Jarstfer, Michael||University of North Carolina at Chapel Hill|
|NrCAM, a candidate susceptibility gene for visual processing deficits in autism||Maness, Patricia||University of North Carolina at Chapel Hill|
|Preclinical testing of novel oxytocin receptor activators in models of autism phenotypes||Moy, Sheryl||University of North Carolina at Chapel Hill|
|IACC Strategic Plan Objective||2008||2009||2010||2011||2012||Total|
|Standardize and validate at least 20 model systems (e.g., cellular and/or animal) that replicate features of ASD and will allow identification of specific molecular targets or neural circuits amenable to existing or new interventions by 2012.
IACC Recommended Budget: $75,000,000 over 5 years
|4.S.B. Funding: The recommended budget was met. Significantly more than the recommended minimum budget was allocated to projects specific to this objective.
Progress: More than 90 projects were supported to develop animal models.
Remaining Gaps, Needs, and Opportunities: Planning Group members discussed whether the amount of investment in this area is appropriate when compared to investments in clinical trials and other later stage studies. Invited experts suggested that the current stage of scientific research in ASD requires pre-clinical research to identify targets from animal and cellular models. Similar to cancer treatment development pathways, which spanned 20-30 years, research in ASD must invest in model systems to understand the fundamental biology from which translation to the clinic can be built. The translational validity of research in non-human animals cannot be determined until human trials are conducted, thus the need for rapid progress to clinical studies in humans is important.